This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakano, N. Articles by Ogihara, T. Search for Related Content PubMed PubMed Citation Articles by Nakano, N. Articles by Ogihara, T.

(Hypertension. 1998;32:444-451.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Negative Regulation of Local Hepatocyte Growth Factor Expression by Angiotensin II and Transforming Growth Factor-ß in Blood Vessels

Potential Role of HGF in Cardiovascular Disease

Nobuaki Nakano; Ryuichi Morishita; Atsushi Moriguchi; Yoshio Nakamura; Shin-ichiro Hayashi; Motokuni Aoki; Iwao Kida; Kunio Matsumoto; Toshikazu Nakamura; Jitsuo Higaki; ; Toshio Ogihara

From the Department of Geriatric Medicine (N.N., R.M., A.M., Y.N., S.H., M.A., I.K., J.H., T.O.) and the Division of Biochemistry (K.M., T.N.), Biomedical Research Center, Osaka University Medical School, Osaka, Japan.

Correspondence to Toshio Ogihara, MD, PhD, Department of Geriatric Medicine, Osaka University Medical School, 2–2 Yamada-oka, Suita 565, Japan.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Because hepatocyte growth factor (HGF) is a member of the endothelium-specific growth factors, we hypothesized that HGF may play a role in cardiovascular disease. Therefore we first examined the role of local HGF production in endothelial cell (EC) growth. Addition of anti-HGF antibody to EC resulted in a significant decrease in EC number. Moreover, coculture of vascular smooth muscle cells (VSMC) with EC resulted in an increase in EC number that was completely inhibited by anti-HGF antibody, suggesting that HGF secreted from EC and VSMC regulates EC growth in an autocrine-paracrine manner. Interestingly, transforming growth factor (TGF)-ß significantly decreased HGF secretion from EC, whereas interleukin 6 stimulated immunoreactive HGF secretion. In human VSMC, TGF-ß and angiotensin II suppressed local HGF production in a dose-dependent manner. Interestingly, anti–TGF-ß antibody resulted in significant but not complete inhibition of the decrease in local HGF production. To further study the regulation of local HGF production, we used a coculture system. Coculture of VSMC with EC resulted in a significant decrease in local HGF secretion. The decrease in local HGF production by coculture was significantly attenuated by anti–TGF-ß antibody, suggesting that inhibition of local HGF production in the coculture system was due to TGF-ß activation. Moreover, a further decrease in local HGF production in the coculture system by angiotensin II was also observed. Finally, we studied the role of angiotensin II in the regulation of the local HGF system in vivo by using a balloon injury rat model. Of importance, local HGF production was significantly decreased in balloon-injured arteries compared with intact vessels, accompanied by a reduction of HGF mRNA. An angiotensin-converting enzyme inhibitor (cilazapril) or an angiotensin II type 1 receptor antagonist (E-4177) significantly stimulated local vascular HGF production associated with the inhibition of neointimal formation after balloon injury compared with vehicle. In contrast, hydralazine did not alter local HGF production or neointimal formation despite decreasing blood pressure to a similar level as that in rats treated with cilazapril or E-4177. Overall, local HGF secretion from vascular cells was negatively regulated by TGF-ß and angiotensin II. The present study also demonstrated that blockade of angiotensin II significantly inhibited neointimal formation, accompanied by a significant increase in local vascular HGF production in vivo in the balloon injury model. Given the strong mitogenic activity of HGF on endothelial cells, increased local HGF production by blockade of angiotensin II may enhance reendothelialization after balloon injury. Downregulation of the local vascular HGF system by TGF-ß and vascular angiotensin may play an important role in the pathogenesis of cardiovascular diseases.

Key Words: endothelium • muscle, smooth, vascular • autocrine-paracrine • restenosis • remodeling

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Endothelial cells are known to secrete various vasoactive substances. Recently, it has been hypothesized that endothelial cells may also modulate vascular growth because many antiproliferative factors are secreted by endothelial cells.^{1 2} It is apparent that dysfunction of endothelial cells may promote abnormal vascular growth such as in atherosclerosis. Given the importance of endothelial cells, we hypothesize that rapid regeneration of endothelial cells not accompanied by growth of vascular smooth muscle cells (VSMC) may have therapeutic potential in abnormal vascular growth such as neointimal formation after angioplasty. From this viewpoint, we have previously reported that hepatocyte growth factor (HGF) has a unique characteristic to stimulate only endothelial cell growth but not VSMC growth.^{3 4} Moreover, the presence of HGF and its specific receptor, c-met, has been detected in vascular tissues.⁵ However, there are no reports as to how HGF is regulated in vascular tissues. HGF is well known as a mesenchyme-derived pleiotropic factor that regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis.^{6 7 8} Therefore knowledge of HGF regulation would be important in understanding the pathophysiology of vascular diseases. In restenosis after angioplasty and atherosclerosis, the contribution of growth factors and cytokines has been reported.^{9 10 11 12 13} For example, transforming growth factor (TGF)-ß, which has bifunctional effects on cell growth, is known to be upregulated in restenosis after angioplasty and atherosclerosis.^{11 12 13} In addition, activation of angiotensin II is also believed to play an important role in the pathogenesis of cardiovascular disease.^{14 15 16 17} Therefore we examined the regulation of local HGF secretion by TGF-ß and angiotensin II in vascular cells. Moreover, the role of angiotensin II in the regulation of the local HGF system was also studied in vivo with a balloon injury rat model.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
In Vitro Experiment
Cell Culture
Human aortic endothelial cells and human aortic VSMC (passage 5) were obtained from Clonetech Corp and cultured in modified MCDB131 medium with 5% fetal calf serum, 10 ng/mL epidermal growth factor, 2 ng/mL basic fibroblast growth factor (bFGF), and 1 mmol/L dexamethasone.^{3 4 5} These cells showed the specific characteristics of endothelial cells and VSMC by immunohistochemical and morphologic observation. All the cells were used within passage 5 to 6.

Cell Counting Assay
In the preparation of experiments for determination of cell count, the cells were grown to subconfluence. After cells reached 80% confluence, the medium was changed to fresh defined serum-free medium (DSF) containing antibody or control.¹⁸ The cells were then incubated overnight. On day 1, the medium was again changed to fresh DSF. On day 4, an index of cell proliferation was determined with a WST cell counting kit (Wako).^{3 4 19}

Coculture
(1) Coculture of quiescent, subconfluent endothelial cells with confluent VSMC (coculture 1; see Figure 2): Human aortic VSMC were seeded onto cell culture inserts (Becton Dickinson, 3.0 µm pore size) and were grown in 10% Dulbecco's modified Eagle's medium (DMEM) to reach confluence. Human endothelial cells were seeded onto 6-well plates (Becton Dickinson), maintained in 10% DMEM and placed in DSF for 48 hours after confluence. At 60% confluence of endothelial cells, the inserts containing VSMC were put into the wells containing the quiescent endothelial cells.²⁰ Endothelial cells were cocultured for 48 hours with VSMC in 0.1% fetal calf serum with anti-HGF antibody or immunoglobulin G (IgG) control.

View larger version (41K): [in this window] [in a new window]   Figure 2. Effect of addition of neutralizing anti-HGF antibody on increased endothelial cell growth by coculture with VSMC. Left drawing illustrates coculture system 1 (see "Methods"). n=8 per group. VSMC(-) indicates endothelial cells without coculture with VSMC; VSMC(+), endothelial cells cocultured with VSMC; VSMC(+) + IgG Control, endothelial cells cocultured with VSMC with addition of normal IgG; VSMC (+) + HGF Ab, endothelial cells cocultured with VSMC with addition of neutralizing anti-HGF antibody. **P<0.01 vs VSMC(-), ##P<0.01 vs VSMC(+).

(2) Coculture of quiescent, confluent VSMC with confluent endothelial cells (coculture 2; see Figure 6a): Human aortic endothelial cells were seeded onto cell culture inserts (Becton Dickinson, 3.0 µm pore size) and were grown in 10% DMEM. Human VSMC were seeded onto 6-well plates (Becton Dickinson), maintained in 10% DMEM, and placed in DSF for 48 hours after confluence. At confluence of VSMC, the inserts containing endothelial cells were put into the wells containing the quiescent VSMC.²⁰ VSMC were cocultured for 24 hours with endothelial cells in DSF, and the concentration of HGF in the medium was determined by enzyme immunoassay (EIA).

View larger version (52K): [in this window] [in a new window]   Figure 6. a, Concentration of HGF released from human aortic VSMC and endothelial cells in coculture of VSMC with human aortic endothelial cells. Left drawing illustrates coculture system 2 (see "Methods"). n=8 per group. EC(-) indicates without endothelial cells; EC(+), with endothelial cells; +Ang II, angiotensin II (10-6 mol/L) added. **P<0.01 vs EC(-), ##P<0.01 vs EC(+). b, Effect of neutralizing anti–TGF-ß antibody on decrease in local HGF production in human VSMC and endothelial cells in coculture of VSMC with endothelial cells. n=8 per group. EC(-) indicates VSMC without endothelial cells; EC(+), VSMC with endothelial cells; +IgG control, VSMC with endothelial cells with addition of normal IgG; +TGF Ab, VSMC with endothelial cells with addition of neutralizing anti–TGF-ß antibody. **P<0.01 vs EC(-).

Effect of Neutralizing Anti-HGF Antibody
The effect of endogenously produced HGF was examined by a neutralization procedure with the use of rabbit anti-human HGF antibody.²¹ For the antibody, the IgG fraction (purified with protein A-agarose) was able to neutralize a biological activity of 10 ng/mL HGF, at a concentration of 10 µg/mL. Normal rabbit serum IgG fraction (10 µg/mL) was used as a control. Cell number in the following groups was examined for both types of the human vascular cells: Protocol 1, group 1: incubation of endothelial cells with anti-HGF antibody (final 10 µg/mL) for 48 hours; group 2: incubation of endothelial cells with normal IgG (final 10 µg/mL) for 48 hours; Protocol 2, group 1: incubation of endothelial cells cocultured with VSMC with anti-HGF antibody (10 µg/mL) for 48 hours; group 2: incubation of endothelial cells cocultured with VSMC with normal IgG (10 µg/mL); and group 3: incubation of endothelial cells without VSMC with normal IgG (10 µg/mL).

Measurement of HGF in Conditioned Medium
Human endothelial cells and VSMC were seeded on 6-well plates (Corning) at a density of 5x10⁴ cells/cm². After replacing the medium with fresh DSF and after culture for 24 hours, the concentration of HGF in the medium was determined by EIA with the use of anti-human HGF antibody.^{3 4 22} This enzyme-linked immunosorbent assay (ELISA) specifically detects rat or human HGF by lack of cross-reactivity of the antibodies.^{21 22}

ELISA and Western Blotting of TGF-ß
Conditioned medium was collected from confluent VSMC maintained in DSF 48 hours later, centrifuged at 600g for 10 minutes, and stored at -20°C. ELISA for immunoreactive TGF-ß₁ in the supernatant was performed with an ELISA kit (Amersham). The antibody against TGF-ß₁ cross-reacts with rat active TGF-ß₁ but not with latent rat TGF-ß₁, TGF-ß₂, or TGF-ß₃. After conversion of TGF-ß from the inactive to the active form by the addition of hydrochloride, measurement of latent TGF-ß was performed by ELISA.²³ Western blotting was also performed for analysis of TGF-ß protein.

Effect of Neutralizing Anti–TGF-ß Antibody
Augmentation of decreased local HGF production in human endothelial cells and VSMC was characterized as TGF-ß specific by a neutralization procedure, with the use of rabbit anti-human TGF-ß (R&D Research).²³ The IgG fraction (purified with protein A-agarose) was able to neutralize the biological activity of TGF-ß. Normal rabbit serum IgG fraction was used as a control.

In Vivo Experiment
Experimental Design
Male Wistar-Kyoto rats (15 weeks-old; Charles River Breeding Laboratories) were anesthetized with ketamine, and the left common carotid artery was surgically exposed.²⁴ A cannula was introduced into the common carotid through the external carotid artery. After balloon injury, blood flow to the common carotid was restored by release of the ligatures and the wound was then closed. Male Wistar-Kyoto rats were divided into 4 groups and treated from 1 week before injury to 2 weeks after operation as follows: vehicle (distilled water), cilazapril (10 mg/kg per day), E-4177 (30 mg/kg per day), or hydralazine (8 mg/kg per day) (n=13). The drugs were kindly donated by Eisai Pharmaceutical Company. The animals were randomly allocated to each group, and the drug was administrated by gavage. After treatment, the rats were killed by decapitation and blood was collected. Systolic blood pressure was measured in conscious rats by the tail-cuff method with a sphygmomanometer (Softron Co Ltd).

Reverse Transcription–Polymerase Chain Reaction/Southern Blotting
RNA was extracted from intact normal vessels from sham-operated rats and balloon-injured vessels at 14 days after injury by RNAzol (Tel-Test Inc). Levels of HGF and G3PDH mRNAs were measured by reverse transcription–polymerase chain reaction (RT-PCR).⁵ The HGF 5' primer (nucleotides 1409 to 1426 of human sequence) was 5'-ATG-CTC-ATG-GAC-CCT-GGT-3'; the 3' primer (nucleotides 1797 to 1814 of human sequence) was 5'-GCC-TGG-CAA-GCT-TCA-TTA-3' (423 bp). Extreme care was taken to avoid contamination of tissue samples with trace amounts of experimental RNA. Aliquots of RNA (0.5 µg) derived from cultured cells were amplified simultaneously by PCR (30 cycles) by individuals who were blinded to the identity of the samples and compared with a negative control (primers without RNA). In the preliminary experiments, the number of amplification cycles for each gene was examined by performing RT-PCR for 20, 15, 30, 35, and 40 cycles. PCR products were within the linear logarithmic phase of the amplification curve until 40 cycles were performed. To ensure that the RT-PCR–amplified product reflects transcribed HGF RNA without significant DNA contamination, RNA samples treated with RNase A or amplified without reverse transcriptase were simultaneously amplified as negative controls. These samples did not result in a visual band. Moreover, PCR products were cut by restriction enzymes, and the fragments were identical to the theoretical bands. The PCR products then were blotted by capillary transfer onto membranes for Southern blotting.

Histological Studies
For histological analyses, a segment of each artery was fixed with 4% paraformaldehyde. Medial and luminal area were measured on a digitizing tablet (South Micro Instruments, model 2200) after staining with hematoxylin.²⁴ The medial area was readily demarcated as the vessel area between the internal and external elastic laminae. At least 3 individual sections from the middle of the transfected arterial segments were analyzed. Animals were coded so that the analysis was performed without knowledge of which treatment each individual animal received.

Measurement of Serum and Tissue HGF Concentration
Serum and tissue HGF concentration was determined by EIA with anti-rat HGF antibodies (HGF EIA kit, Tokushumeneki Research Center).^{3 21 22} The carotid arteries were promptly removed without excess fat after perfusion from the apex of the heart with saline, frozen in liquid nitrogen, and stored at -70°C until use. On the day of the extraction, the tissue was thawed at 4°C and homogenized by Polytron in assay solution. Each specimen was centrifuged at 20 000g for 30 minutes at 4°C to remove the lysates. Tissue HGF concentration was determined by EIA with anti-rat HGF antibody.^{21 22}

Statistical Analysis
All values are expressed as mean±SEM. ANOVA with subsequent Bonferroni/Dunnett's test was used to determine the significance of differences in multiple comparisons. Values of P<0.05 were considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
In Vitro Experiments
The presence of HGF and its receptor (c-met) mRNAs was detected in endothelial cells and VSMC of rat and human by RT-PCR.³ The secretion of HGF was also readily detected by ELISA with specific human anti-HGF antibody in human endothelial cells and VSMC.³ Therefore we initially studied the role of endogenously produced HGF from vascular cells in endothelial cell growth. Addition of neutralizing antibody against human HGF to human aortic endothelial cells resulted in a significant decrease in the number of endothelial cells (P<0.01, Figure 1), whereas IgG control did not alter endothelial cell number. Moreover, we used coculture system 1 (see "Methods"; Figure 2) to clarify the role of local HGF production from VSMC in endothelial growth. As shown in Figure 2, coculture of VSMC with endothelial cells resulted in a significant increase in number of endothelial cells compared with endothelial cells alone (P<0.01), revealing that factors that stimulated endothelial cells were secreted from VSMC. Importantly, the increase in number of endothelial cells was significantly attenuated by coincubation with anti-HGF antibody (P<0.01). These results demonstrated that local HGF production from endothelial cells and VSMC regulated growth of endothelial cells in an autocrine-paracrine manner.

View larger version (42K): [in this window] [in a new window]   Figure 1. Inhibition of endothelial cell growth by addition of neutralizing anti-HGF antibody in endothelial cells. n=8 per group. Vehicle indicates endothelial cells alone; IgG Control, endothelial cells with addition of normal IgG; HGF Ab, endothelial cells with addition of neutralizing anti-HGF antibody. **P<0.01 vs Vehicle, ##P<0.01 vs IgG Control.

We therefore examined the regulation of local HGF production in vascular cells. Interestingly, addition of TGF-ß significantly inhibited HGF secretion into the culture medium of endothelial cells compared with basal secretion (P<0.01, Figure 3), whereas bFGF and interleukin (IL)-6 stimulated it (Figure 3). Next, we examined the regulation of HGF in human aortic VSMC. In VSMC, TGF-ß significantly decreased immunoreactive HGF release into the culture medium of VSMC as compared with vehicle treatment (Figure 4a), which was abolished by addition of neutralizing anti–TGF-ß antibody (data not shown). The inhibitory effect of TGF-ß on local HGF production was dose-dependent (Figure 4b). In contrast, IL-6 stimulated the release of HGF significantly, whereas bFGF had no effect on HGF. Moreover, we tested whether angiotensin II affects local HGF production in VSMC. Interestingly, angiotensin II also significantly decreased vascular HGF production in a dose-dependent manner (Figure 5a). As previously reported, angiotensin II stimulated TGF-ß expression in VSMC.²³ Therefore, to elucidate the participation of TGF-ß stimulation by angiotensin II in decreased local HGF production, we studied the effect of neutralizing anti–TGF-ß antibody on the angiotensin II–induced decrease in local HGF production in VSMC that secreted latent and active TGF-ß as assessed by Western blotting (Figure 5c). Interestingly, neutralizing anti–TGF-ß antibody resulted in significant but not complete inhibition of local HGF production by angiotensin II (Figure 5b). During the experimental period (24 hours after stimulation), neither angiotensin II nor TGF-ß altered VSMC growth (DSF, 0.359±0.015; angiotensin II, 0.362±0.036; TGF-ß, 0.357±0.011; not significant).

View larger version (35K): [in this window] [in a new window]   Figure 3. Effect of various cytokines on concentration of HGF released from human aortic endothelial cells. n=8 per group. DSF indicates vehicle; TGF, human recombinant TGF-ß (10 ng/mL) added to endothelial cells; FGF, human recombinant bFGF (10 ng/mL) added to endothelial cells; IL-6, human recombinant IL-6 (50 ng/mL) added to endothelial cells. **P<0.01, *P<0.05 vs DSF.

View larger version (41K): [in this window] [in a new window]   Figure 4. a, Effect of various cytokines on concentration of HGF released from human aortic VSMC. n=8 per group. DSF indicates vehicle; TGF, human recombinant TGF-ß (10 ng/mL) added to VSMC; FGF, human recombinant bFGF (10 ng/mL) added to VSMC; IL-6, human recombinant IL-6 (50 ng/mL) added to VSMC. **P<0.01 vs DSF. b, Effect of TGF-ß on concentration of HGF released from human aortic VSMC. n=8 per group. DSF indicates vehicle; TGF, human recombinant TGF-ß (0.1 to 10 ng/mL) added to VSMC. **P<0.01 vs DSF, ##P<0.01 vs 0.1 ng/mL.

View larger version (18K): [in this window] [in a new window]   Figure 5. a, Effect of angiotensin II on concentration of HGF released from human aortic VSMC. n=8 per group. DSF indicates vehicle; Ang II, angiotensin II (10-6 to 10-8 mol/L) added to VSMC. **P<0.01 vs DSF, #P<0.05 vs angiotensin II 10-8 mol/L, +P<0.05 vs angiotensin II 10-7 mol/L. b, Effect of neutralizing anti–TGF-ß antibody on angiotensin II–induced local HGF production in human VSMC. n=8 per group. UN indicates vehicle; +IgG, VSMC with addition of normal IgG; +Ab, VSMC with addition of neutralizing anti–TGF-ß antibody; +Ang II, angiotensin II (10-6mol/L) added to VSMC. **P<0.01 vs UN. c, Western blot of active and latent TGF-ß in conditioned medium of cultured human VSMC.

To evaluate the effect of activation of TGF-ß in vascular tissues, we used a coculture system of VSMC with endothelial cells (see "Methods"; Figure 6a). Coculture of VSMC with endothelial cells resulted in a significant decrease in local HGF production by VSMC, probably through TGF-ß activation (Figure 6a), because latent TGF-ß is known to be converted to active by contact with endothelial cells. Indeed, active TGF-ß could be detected in conditioned medium of cocultured VSMC with endothelial cells by the use of ELISA (coculture of VSMC with endothelial cells, 2.55±0.13 pg/mL; endothelial cells alone, 1.15±0.24 pg/mL; VSMC alone, 0.05±0.01 pg/mL). Decrease in local HGF production by coculture was almost completely attenuated by neutralizing anti–TGF-ß antibody (Figure 6b), suggesting that inhibition of local HGF production by coculture was due to the activation of TGF-ß. In the coculture system, angiotensin II also caused a further reduction of local HGF production compared with coculture alone (Figure 6a).

In Vivo Experiments
We further examined the effect of angiotensin II on local vascular HGF production in a balloon injury rat model because the significant contribution of angiotensin II and TGF-ß is well known in the pathogenesis of neointimal formation in this model.^{10 11 12 13 14 15} Indeed, a marked reduction of vascular HGF mRNA was observed in injured vessels compared with normal vessels, whereas no apparent change in G3PDH mRNA was observed between normal uninjured vessels and injured vessels at 14 days after balloon injury (Figure 7). Therefore rats were treated with cilazapril (an angiotensin-converting enzyme [ACE] inhibitor), E-4177 (an angiotensin-1 receptor antagonist), hydralazine, and vehicle between 7 days and 14 days after balloon injury. Treatment of rats with cilazapril, E-4177, or hydralazine for 3 weeks significantly decreased systolic blood pressure (P<0.05) compared with rats treated with vehicle (data not shown). Heart rate did not differ among all the groups (data not shown). Nevertheless, administration of cilazapril and E-4177 but not hydralazine resulted in significant inhibition of neointimal formation after balloon injury (Figure 8, a and b, P<0.01). In contrast, no significant changes in medial areas were observed among groups (vehicle, 0.140±0.010; hydralazine, 0.141±0.016; cilazapril, 0.139±0.013; E-4177, 0.138±0.025 mm²; not significant). Consistent with the decreased local HGF mRNA in balloon-injured vessels, local HGF production was also significantly decreased in balloon-injured vessels compared with normal intact artery (P<0.01, Figure 8c). In contrast, vascular HGF concentration was significantly increased in balloon-injured rats treated with cilazapril or E-4177 compared with vehicle (Figure 8c, P<0.01), whereas there was no significant change in rats treated with vehicle or hydralazine. On the other hand, no significant change in serum HGF concentration was observed in balloon-injured and sham-operated rats. The inhibitory effect of cilazapril and E-4177 was not accompanied by an increase of serum HGF concentration (Figure 8d, P>0.05). Similarly, the other groups also failed to show any increase in serum HGF concentration.

View larger version (35K): [in this window] [in a new window]   Figure 7. Expression of HGF (a) assessed by RT-PCR/Southern blotting and G3PDH mRNA (b) assessed by RT-PCR in the balloon-injured vessels and intact uninjured vessels. NC indicates negative control (no RNA); injury (1 through 3), balloon-injured vessels at 14 days after injury; normal (4 through 6), intact uninjured vessels in sham-operated rats. n=3 per group.

View larger version (83K): [in this window] [in a new window]   Figure 8. a, Typical example of carotid arteries of rats treated with cilazapril, E-4177, hydralazine, or vehicle after balloon injury. uninjured indicates rats without balloon injury; vehicle, rats treated with vehicle; hydralazine, rats treated with hydralazine; cilazapril, rats treated with cilazapril; E-4177, rats treated with E-4177. b, Effects of cilazapril, E-4177, and hydralazine on neointimal/medial area after balloon injury. n=6 to 7 per group. **P<0.01 vs hydralazine. c, Percent inhibition of local HGF production after balloon injury in rats treated with cilazapril, E-4177, hydralazine, and vehicle. n=4 to 6 per group. Normal indicates rats without balloon injury; Vehicle, balloon-injured rats treated with vehicle; Cilazapril, balloon-injured rats treated with cilazapril; Hydralazine, balloon-injured rats treated with hydralazine; E-4177, balloon-injured rats treated with E-4177. **P<0.01 vs Normal, ##P<0.01 vs Hydralazine. d, Effects of cilazapril, E-4177, and hydralazine on serum HGF concentration after balloon injury. n=4 to 6 per group.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Endothelial cells may have potential therapeutic actions in abnormal VSMC growth through the secretion of multiple endothelium-derived substances that have profound influences on vascular smooth muscle function.^{1 2} From this viewpoint, we sought an endothelium-specific growth factor that does not stimulate VSMC growth. As previously reported,³ HGF has the characteristics of an endothelium-specific growth factor, similar to vascular endothelial growth factor (VEGF). VEGF has been reported to be secreted from VSMC and to act on endothelial cells,²⁵ whereas HGF is secreted from endothelial cells and VSMC and acts on endothelial cells, as shown in this study. The local HGF system as well as VEGF is expected to have a role in the pathogenesis of cardiovascular disease, although the regulation of VEGF and HGF has not yet been clarified in vascular tissues. Because anti-HGF antibody attenuated endothelial cell growth, local HGF production in vascular cells may have a pathophysiological role in endothelial growth in an autocrine-paracrine manner. Therefore, the regulation of local HGF production is noteworthy. In this study, we examined the effects of angiotensin II and TGF-ß on HGF secretion from vascular cells to study the cytokine network around the local HGF system.

We focused on the interaction of TGF-ß with the HGF system because TGF-ß was increased in atherosclerotic lesions and restenotic lesions after angioplasty.^{11 12 13} Our present study documented a marked reduction of local HGF production by TGF-ß treatment in human aortic endothelial cells and VSMC. Inhibition of local HGF production by TGF-ß is also suggested by the observation that coculture of VSMC with endothelial cells resulted in a significant decrease in HGF production by VSMC, because the conversion of latent into active TGF-ß is well known in coculture of VSMC with endothelial cells.^{16 17 26} Indeed, neutralizing anti–TGF-ß antibody attenuated the inhibition of local HGF production by coculture system. Local HGF mRNA expression in VSMC was also decreased by TGF-ß treatment (unpublished observation). Because the promoter region of HGF gene contains various binding sites for transcriptional factors, for example, a TGF-ß–inhibitory element and a cAMP responsive element,²⁷ TGF-ß inhibits local HGF production probably through a TGF-ß inhibitory element. In experimental hypertensive and restenosis models, activation of the vascular renin-angiotensin and TGF-ß was also reported in the vasculature.^{10 11 12 13 14 15 28 29} In vitro studies also revealed that angiotensin II stimulates TGF-ß gene expression in VSMC.²³ Of importance, the present study demonstrated that angiotensin II also results in a significant decrease in local HGF production in VSMC. Moreover, inhibition of local HGF production by angiotensin II was still observed in coculture of VSMC with endothelial cells. Because neutralizing anti–TGF-ß antibody did not completely attenuate the decrease in local HGF production by angiotensin II, inhibition of local HGF production by angiotensin II may be mediated by angiotensin II–specific mechanisms, for example, decrease in cAMP, in addition to TGF-ß induced by angiotensin II. Taken together, activation of the local TGF-ß and vascular renin-angiotensin system may negatively regulate local HGF production in vascular tissues. Suppression of local HGF production might be important to maintain endothelial function because HGF prevents apoptosis of endothelial cells mediated by several conditions.³⁰

This phenomenon provides the interesting hypothesis that disruption of the autocrine-paracrine local HGF system, which maintains endothelial cell growth by TGF-ß and angiotensin II, may result in abnormal growth of VSMC because endothelial cells secrete antiproliferative substances (see Figure 9; 1, 2). Therefore we further examined the pathophysiological roles of the vascular HGF system in cardiovascular disease. More importantly, the present study demonstrated a significant decrease in local vascular HGF production in the rat balloon injury model. Contribution of vascular angiotensin II and TGF-ß in the pathogenesis of neointimal formation is well known.^{10 11 12 13 14 15} Moreover, blockade of angiotensin II or TGF-ß inhibited neointimal formation in this model.^{10 14} Thus an ACE inhibitor or an angiotensin-1 receptor antagonist was administered in the balloon injury model to study the role of angiotensin II in the downregulation of local vascular HGF. Expectedly, blockade of angiotensin II by cilazapril or E-4177 significantly stimulated local HGF production associated with the inhibition of neointimal formation, whereas hydralazine did not. Because HGF is an endothelium-specific growth factor,^{3 4} increased local HGF production probably would stimulate regeneration of endothelial cells after balloon injury. It is noteworthy that administration of an ACE inhibitor restored endothelial dysfunction after percutaneous transluminal coronary angioplasty in human subjects³¹ and that treatment with ACE inhibitors improved endothelial dysfunction in human hypertensive patients.³² Increased local HGF production may participate in the improvement of endothelial dysfunction observed in those cases treated by blockers of angiotensin II. Additionally, our preliminary results showed that in vivo gene transfer of HGF into balloon-injured artery resulted in significant inhibition of neointimal formation by reendothelialization.³³ Increased local HGF production itself by blockade of angiotensin II may have therapeutic value against abnormal VSMC growth through the stimulation of reendothelialization, in addition to the blockade of angiotensin II–mediated VSMC growth. As angiotensin II stimulated TGF-ß in VSMC, increased TGF-ß may also participate in the downregulation of local HGF production.

View larger version (23K): [in this window] [in a new window]   Figure 9. Hypothesis in the role of HGF in the maintenance of the vascular structure. In static state, HGF secreted from VSMC and endothelial cells may maintain vascular structure in an autocrine-paracrine manner, whereas endothelial cells may inhibit VSMC growth through production of antiproliferative substances (nitric oxide [NO], prostaglandin I2 [PGI2], C-type natriuretic peptide [CNP], and so on) as a biological barrier. In contrast, in balloon-injured vessels, impairment of the endothelial cells may occur through downregulation of local HGF production by TGF-ß and/or angiotensin II. Therefore, proliferation of VSMC may be accelerated by loss of antiproliferative substances.

Although the exact mechanisms of HGF regulation are not yet understood, these data demonstrate that TGF-ß and angiotensin II suppressed local vascular HGF production. Moreover, we demonstrated that cilazapril and E-4177 but not hydralazine significantly inhibited neointimal formation, accompanied by a significant increase in local vascular HGF production. Given the strong mitogenic activity of HGF on endothelial cells, increased local vascular HGF production by angiotensin II blockade may have therapeutic value against abnormal VSMC growth by enhancing reendothelialization after balloon injury. Negative regulation of local HGF production by angiotensin II and TGF-ß may have physiological roles in vascular disease, given the activation of the vascular TGF-ß and vascular renin-angiotensin system in atherosclerosis, restenosis, and hypertension in humans and experimental models.^{10 11 12 13 14 15 28 29}

	Acknowledgments

 
Dr Ryuichi Morishita is the recipient of a Harry Goldblatt Award from the Council of High Blood Pressure, the American Heart Association. This work was supported in part by grants from the Japan Heart Foundation–Pfizer Pharmaceuticals Grant for Research on Coronary Artery Disease, Sagawa Cancer Foundation, and Uehara Memorial Foundation. We wish to thank Chihiro Noguchi for excellent technical assistance.

Received January 26, 1998; first decision February 9, 1998; accepted May 11, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Dzau VJ. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle cells and cardiac myocytes. Curr Opin Nephrol Hypertens. 1993;2:27–32.[Medline] [Order article via Infotrieve]
2. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension. 1991;18(suppl III):III-115–III-121.
3. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T. A vascular modulator, hepatocyte growth factor, is associated with systolic blood pressure. Hypertension. 1996;28:409–413.[Abstract/Free Full Text]
4. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Nakano H, Matsumoto K, Nakamura T, Ogihara T. Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors: additive stimulatory effect of HGF with basic fibroblast growth factor, but not vascular endothelial growth factor. J Hypertens. 1996;14:1067–1072.[Medline] [Order article via Infotrieve]
5. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, Yamada K, Hayashi S, Yo Y, Matsumoto K, Nakamura T, Ogihara T. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun. 1995;215:483–488.[Medline] [Order article via Infotrieve]
6. Matsumoto K, Nakamura T. Roles of HGF as a pleiotropic factor in organ regeneration. In: Goldberg ID, Rosen EM, eds. Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and C-Met Receptor. Basel, Switzerland: Birkhauser Verlag; 1993;225–249.
7. Ponzetto C, Bardelli A, Zhen Z, Maina F, Zonca P, Giordano S, Graziani A, Panayoyou G, Comoglio PM. A multifunctional docking site mediates signaling and transformation by the HGF/SF receptor family. Cell. 1994;77:261–271.[Medline] [Order article via Infotrieve]
8. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol. 1994;127:1783–1787.[Abstract/Free Full Text]
9. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47–III-52.
10. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-ß1 suppress intimal hyperplasia in a rat model. J Clin Invest. 1994;93:1172–1178.
11. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta-1 during repair of arterial injury. J Clin Invest. 1991;88:904–910.
12. Rakugi H, Gibbons GH, Wang D, Billingham M, Vershave K, Feruson J, Angelini P, Hogan P, Massumi A, Buja LM, Blubb F, McAllister H, Willerson H, Dzau VJ. Expression of transforming growth factor beta 1 in human atherectomy specimens from primary and restenotic coronary artery lesions. J Am Coll Cardiol. 1992;19:329A. Abstract.
13. Nikol S, Isner M, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-ß1 is increased in human vascular restenosis lesions. J Clin Invest. 1992;90:1582–1592.
14. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186–188.[Abstract/Free Full Text]
15. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest. 1994;93:339–346.
16. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J, Heldin CH, Rifkin DB. Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J Cell Biol. 1993;120:995–1002.[Abstract/Free Full Text]
17. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol. 1990;111:757–763.[Abstract/Free Full Text]
18. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217–223.[Medline] [Order article via Infotrieve]
19. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull (Tokyo).. 1993;41:1118–1122.
20. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, Ogihara T, Dzau VJ. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest. 1994;94:824–829.
21. Tsuda H, Iwase T, Matsumoto K, Ito M, Hirono I, Nishida Y, Yamamoto M, Tatematsu M, Matsumoto K, Nakamura T. Immunohistochemical localization of hepatocyte growth factor protein in pancreas islet A-cells of man and rats. Jpn J Cancer Res. 1992;83:1262–1266.[Medline] [Order article via Infotrieve]
22. Yamada A, Matsumoto K, Iwanari H, Sekiguchi K, Kawata S, Matsuzawa Y, Nakamura T. Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues. Biomed Res. 1995;16:105–114.
23. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456–461.
24. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474–8478.[Abstract/Free Full Text]
25. Ferrara N, Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors. 1991;5:141–148.[Medline] [Order article via Infotrieve]
26. Sato Y, Okada F, Abe M, Seguchi T, Kuwano M, Sato S, Furuya A, Hanai N, Tamaoki T. The mechanism for the activation of latent TGF-beta during co-culture of endothelial cells and smooth muscle cells: cell-type specific targeting of latent TGF-beta to smooth muscle cells. J Cell Biol. 1993;123:1249–1254.[Abstract/Free Full Text]
27. Okajima A, Miyazawa K, Kitamura N. Characterization of the promoter region of the rat hepatocyte-growth-factor/scatter-factor gene. Eur J Biochem. 1993;213:113–119.[Medline] [Order article via Infotrieve]
28. Morishita R, Higaki J, Miyazaki M, Ogihara T. Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension. 1992;19(suppl II):II-62–II-67.
29. Sarzani R, Brecher P, Chobanian AV. Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest. 1989;83:1404–1498.
30. Morishita R, Higaki J, Hayashi S, Yo Y, Aoki M, Nakamura S, Moriguchi A, Matsushita H, Matsumoto K, Nakamura T, Ogihara T. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia. 1997;40:1053–1061.[Medline] [Order article via Infotrieve]
31. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258–265.[Abstract/Free Full Text]
32. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation. 1996;94:3115–3122.[Abstract/Free Full Text]
33. Nakamura S, Moriguchi A, Morishita R, Higaki J, Kaneda Y, Nakamura T, Ogihara T. Re-endothelialization therapeutics for restenosis: in vivo gene transfer of human hepatocyte growth factor resulted in an inhibition of neointimal formation after balloon injury, accompanied by restore of nitric oxide. Circulation. 1997;96(suppl I):I-670. Abstract.

This article has been cited by other articles:

				N. Shigemura, M. Okumura, S. Mizuno, Y. Imanishi, A. Matsuyama, H. Shiono, T. Nakamura, and Y. Sawa Lung Tissue Engineering Technique with Adipose Stromal Cells Improves Surgical Outcome for Pulmonary Emphysema Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1199 - 1205. [Abstract] [Full Text] [PDF]

				K. Iwata, Y. Sawa, S. Kitagawa-Sakakida, N. Kawaguchi, N. Matsuura, T. Nakamura, and H. Matsuda Gene transfection of hepatocyte growth factor attenuates the progression of cardiac remodeling in the hypertrophied heart J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 719 - 725. [Abstract] [Full Text] [PDF]

				N. Shigemura, Y. Sawa, S. Mizuno, M. Ono, M. Minami, M. Okumura, T. Nakamura, Y. Kaneda, and H. Matsuda Induction of Compensatory Lung Growth in Pulmonary Emphysema Improves Surgical Outcomes in Rats Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1237 - 1245. [Abstract] [Full Text] [PDF]

				N. Shigemura, Y. Sawa, S. Mizuno, M. Ono, M. Ohta, T. Nakamura, Y. Kaneda, and H. Matsuda Amelioration of Pulmonary Emphysema by In Vivo Gene Transfection With Hepatocyte Growth Factor in Rats Circulation, March 22, 2005; 111(11): 1407 - 1414. [Abstract] [Full Text] [PDF]

				Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF]

				S. Nakamura and T. Niwa Pyridoxal Phosphate and Hepatocyte Growth Factor Prevent Dialysate-Induced Peritoneal Damage J. Am. Soc. Nephrol., January 1, 2005; 16(1): 144 - 150. [Abstract] [Full Text] [PDF]

				Y. Taniyama, R. Morishita, M. Aoki, K. Hiraoka, K. Yamasaki, N. Hashiya, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Angiogenesis and Antifibrotic Action by Hepatocyte Growth Factor in Cardiomyopathy Hypertension, July 1, 2002; 40(1): 47 - 53. [Abstract] [Full Text] [PDF]

				S. Miyagawa, Y. Sawa, S. Taketani, N. Kawaguchi, T. Nakamura, N. Matsuura, and H. Matsuda Myocardial Regeneration Therapy for Heart Failure: Hepatocyte Growth Factor Enhances the Effect of Cellular Cardiomyoplasty Circulation, May 28, 2002; 105(21): 2556 - 2561. [Abstract] [Full Text] [PDF]

				Y. Taniyama, R. Morishita, K. Hiraoka, M. Aoki, H. Nakagami, K. Yamasaki, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model: Molecular Mechanisms of Delayed Angiogenesis in Diabetes Circulation, November 6, 2001; 104(19): 2344 - 2350. [Abstract] [Full Text] [PDF]

				B. C. Berk Vascular Smooth Muscle Growth: Autocrine Growth Mechanisms Physiol Rev, July 1, 2001; 81(3): 999 - 1030. [Abstract] [Full Text] [PDF]

				K. Matsumoto, R. Morishita, A. Moriguchi, N. Tomita, M. Aoki, H. Sakonjo, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model Hypertension, February 1, 2001; 37(2): 270 - 274. [Abstract] [Full Text] [PDF]

				Y. Taniyama, R. Morishita, H. Nakagami, A. Moriguchi, H. Sakonjo, Shokei-Kim, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters Circulation, July 11, 2000; 102(2): 246 - 252. [Abstract] [Full Text] [PDF]

				S.-i. Hayashi, R. Morishita, S. Nakamura, K. Yamamoto, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, K. Matsumoto, T. Nakamura, et al. Potential Role of Hepatocyte Growth Factor, a Novel Angiogenic Growth Factor, in Peripheral Arterial Disease : Downregulation of HGF in Response to Hypoxia in Vascular Cells Circulation, November 9, 1999; 100(90002): II-301 - 308. [Abstract] [Full Text] [PDF]

				K. Matsumoto, R. Morishita, A. Moriguchi, N. Tomita, Y. Yo, T. Nishii, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Prevention of Renal Damage by Angiotensin II Blockade, Accompanied by Increased Renal Hepatocyte Growth Factor in Experimental Hypertensive Rats Hypertension, August 1, 1999; 34(2): 279 - 284. [Abstract] [Full Text] [PDF]

				M. Nishimura, M. Ushiyama, K. Ohtsuka, M. Nishida, N. Inoue, A. Matsumuro, T. Mineo, and M. Yoshimura Serum Hepatocyte Growth Factor as a Possible Indicator of Vascular Lesions J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2475 - 2480. [Abstract] [Full Text]

				R. Morishita, S. Nakamura, S.-i. Hayashi, Y. Taniyama, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, S. Takeshita, K. Matsumoto, et al. Therapeutic Angiogenesis Induced by Human Recombinant Hepatocyte Growth Factor in Rabbit Hind Limb Ischemia Model as Cytokine Supplement Therapy Hypertension, June 1, 1999; 33(6): 1379 - 1384. [Abstract] [Full Text] [PDF]